Advertisement

The Latest

Regentis Biomaterials, a company focused on developing proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding from new investors Royal DSM through its venturing subsidiary, Crossroad Fund, Medica Venture Partners, SCPVitalife and Technion Investment…

Advertisement